Which agent is a common first-line option for MRSA skin infections?

Which agent is a common first-line option for MRSA skin infections?

• A. Linezolid
• B. Cephalexin
• C. Vancomycin
• D. Amoxicillin

Answer: (C)

MRSA infections require an antibiotic that is active against this resistant organism, especially for skin and soft tissue infections that need systemic therapy. Vancomycin fits this need well because it directly inhibits bacterial cell wall synthesis and has reliable activity against MRSA. It’s typically given intravenously in inpatient settings to ensure adequate drug exposure for MRSA SSTIs, with trough level monitoring to manage efficacy and toxicity. In contrast, the beta-lactam options shown (which include cephalexin and amoxicillin) do not cover MRSA well and are generally ineffective against it. Linezolid is active against MRSA and can be used, but it is usually reserved for situations where vancomycin is not suitable or where oral therapy is preferred, due to its longer safety considerations and costs. So vancomycin is the most common first-line choice for MRSA skin infections that require systemic treatment.

MRSA infections require an antibiotic that is active against this resistant organism, especially for skin and soft tissue infections that need systemic therapy. Vancomycin fits this need well because it directly inhibits bacterial cell wall synthesis and has reliable activity against MRSA. It’s typically given intravenously in inpatient settings to ensure adequate drug exposure for MRSA SSTIs, with trough level monitoring to manage efficacy and toxicity. In contrast, the beta-lactam options shown (which include cephalexin and amoxicillin) do not cover MRSA well and are generally ineffective against it. Linezolid is active against MRSA and can be used, but it is usually reserved for situations where vancomycin is not suitable or where oral therapy is preferred, due to its longer safety considerations and costs. So vancomycin is the most common first-line choice for MRSA skin infections that require systemic treatment.